Precigen, Inc. (PGEN) Earnings
Precigen, Inc. is expected to report next earnings on August 11, 2026 (in NaN days), with a consensus EPS estimate of $-0.01. PGEN has beaten EPS estimates in 5 of its last 12 reported quarters (average surprise +26.8% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 13, 2026 | $-0.03 | $-0.02 | +33.3% | $23M | +11.8% |
| Mar 25, 2026 | $-0.10 | $-0.01 | +90.0% | $5M | -45.6% |
| Nov 13, 2025 | $-0.08 | $-0.11 | -37.5% | $3M | -64.7% |
| Aug 12, 2025 | $-0.14 | $-0.11 | +21.4% | $856000 | -8.3% |
| Mar 19, 2025 | $-0.06 | $-0.04 | +33.3% | $1M | +62.3% |
| Nov 14, 2024 | $-0.08 | $-0.09 | -12.5% | $953000 | -26.7% |
| Aug 14, 2024 | $-0.09 | $-0.10 | -11.1% | $717000 | -44.0% |
| Feb 13, 2024 | $-0.08 | $-0.13 | -62.5% | $1M | — |
| Nov 9, 2023 | $-0.08 | $-0.08 | +0.0% | $1M | -18.9% |
| Mar 6, 2023 | $-0.10 | $-0.11 | -10.0% | $2M | -71.6% |
| Nov 9, 2022 | $0.10 | $-0.04 | -140.0% | $17M | +514.8% |
| Mar 1, 2022 | $-0.14 | $-0.13 | +7.1% | $24M | -0.3% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 13, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Paximius Commercial Launch Progress * Paximius received FDA full approval in August 2025, with no treatment restrictions, making it the first commercial therapeutic for RRP. Q1 2026 was the first full quarter of commercial availability, and the launch has shown accelerating revenue growth momentum that has continued into Q2 2026. * As of the call, approximately 400 patients are registered in the Paximius patient hub, 25% of which are from community practices, demonstrating broad adoption beyond major academic medical centers. Total covered insured lives across commercial, Medicare, and Medicaid is 297 million, equal to over 90% of all insured lives in the U.S. * A permanent J-code for Paximius was activated on April 1, 2026, simplifying claims processing and improving patient access. An expert position paper from 16 leading U.S. RRP physicians, published in *The Laryngoscope*, recommends Paximius as the preferred first-line standard of care. - Q1 2026 Financial Performance * Total company revenue hit $23.3 million, driven almost entirely by $21.6 million in Paximius sales. R&D expenses were $5.6 million, a $4.8 million decrease year-over-year, largely because Paximius manufacturing costs were expensed prior to FDA approval. SG&A expenses were $21 million, an $8.7 million increase year-over-year driven by expanded commercial activities for the Paximius launch. * Operating loss for Q1 2026 was $6 million, and net loss was $7.9 million (2 cents per basic/diluted share). The company ended the quarter with $56.7 million in cash, cash equivalents, and investments. Cash used in operations was $43.8 million for the quarter, including $13 million in non-recurring cash outflows that will not repeat in subsequent 2026 quarters. - Pipeline and Operational Updates * Paximius targets the root cause of RRP via a targeted immune response against HPV6/11, with a favorable safety profile that enables potential redosing; an ongoing redosing clinical trial is currently enrolling patients. A pediatric Paximius trial is planned to initiate in Q4 2026. * The marketing authorization application for Proxima is currently under review by the EMA. The company will sponsor the third annual RRP Awareness Day in June 2026 to raise global disease awareness. * PRGN-2009, an immunotherapy built on the same adenovirus platform as Paximius targeting HPV-16/18-driven head and neck and cervical cancers, is advancing in multiple Phase II trials in combination with pembrolizumab. Data updates for PRGN-2009 will be provided in the second half of 2026. * Updated durability data for Paximius will be presented at the ASCO conference in June 2026.
Guidance
- The company expects R&D expenses will increase over the remainder of 2026 as pipeline activities progress. - Cash used in operations for Q2 2026 is expected to be significantly lower than the Q1 2026 level, due to the absence of non-recurring Q1 cash outflows. - Management reaffirms that existing cash, cash equivalents, investments, and expected collection of Paximius receivables are sufficient to fund operations through cash flow breakeven by the end of 2026. No additional capital raising is currently planned. - Management declined to provide specific numerical revenue guidance for Q2 2026, but confirmed the launch is accelerating and positive trends from Q1 are continuing into Q2 and beyond. Management expects continued activation of new prescribing accounts, with community practice adoption strengthening over time.
Segment performance
The company has only one commercial product segment: Paximius (Pepsimios), a treatment for adult RRP. In Q1 2026, Paximius net product revenue was $21.6 million, which contributed 92.7% of the company's total Q1 2026 revenue of $23.3 million. This represents a significant increase from Paximius revenue of $3.4 million in Q4 2025. There are no other revenue-generating product segments reported for the quarter.
Risks & headwinds
- Management noted that all forward-looking statements are based on current expectations, and actual results could differ materially due to inherent risks and uncertainties, as detailed in the company's SEC filings. No specific additional operational or financial risks were disclosed during the call.
Analyst Q&A
Q: Jason Butler (Citizens) asked three key questions: how many patients have received at least one Paximius dose and completed the full treatment course, what are the design details of the Paximius redosing trial and when will initial data be available, and will PRGN-2009 Phase II data be included in the planned 2026 update. /
A: Management declined to disclose the specific number of treated patients, but confirmed that some patients who started dosing in November 2025 (a 12-week regimen) have already completed the full course of treatment. The redosing trial is currently enrolling partial responders from earlier clinical trials, and data collection is ongoing. Management confirmed that PRGN-2009 Phase II trial data, including the head and neck trial in combination with pembrolizumab, will be shared in the second half of 2026.
Q: Brian Chang (JPMorgan) asked about the pace of patient hub recruitment and conversion to commercial treatment, and requested guidance for modeling Q2 and full-year 2026 revenue. /
A: Management noted that revenue growth demonstrates strong conversion progress, and hub recruitment has grown steadily since launch. 25% of hub patients are from community practices, reflecting the drug's expanding reach, and many treated patients are not enrolled in the hub. Management declined to provide specific numerical Q2 guidance, but confirmed that uptake is accelerating, account activation is growing, and community adoption will continue to strengthen, building a long-term foundation for the product.
Q: R.J. (H.C. Wainwright) asked what portion of Q1 Paximius revenue came from pent-up demand/Q4 carryover, how many of the 400 hub patients have been infused, what the average time from enrollment to dosing is, and how the upcoming ASCO durability data will impact the business. /
A: Management confirmed that Q4 to Q1 revenue carryover was minimal, and Q1 revenue growth was driven primarily by new patients. Management stated that additional quarters of data are needed before reporting detailed hub conversion and timeline trends. The ASCO durability data will support potential indication expansion, and further demonstrate the robustness of the company's adenovirus platform for HPV-related indications, including rare disease and oncology.